U.K. MRI developer secures $900K investment, appoints new board member
MRI software company Acuitas Medical has garnered a £700,000 ($899,700 (U.S.) co-investment from Finance Wales and Altima Global Special Opportunities Master Fund towards the development of its MR-based Fine Texture Analysis technology, and has named Sir Michael Brady as non-executive director of the board.
Both the £500,000 ($643,000 U.S.) equity investment by Finance Wales and the £200,000 ($257,000 U.S.) further investment from Altima will go toward clinical studies for the texture analysis technology, which can enable the early diagnosis and management of cancer, organ fibrosis and other diseases, stated the Swansea, England-based company.
Brady, who has agreed to serve as Finance Wales’ representative on the company’s board and consultant to the company, is a professor of information engineering at Oxford University in England and has been involved in the commercialization of imaging technology developed by several enterprises, said Acuitas.
Both the £500,000 ($643,000 U.S.) equity investment by Finance Wales and the £200,000 ($257,000 U.S.) further investment from Altima will go toward clinical studies for the texture analysis technology, which can enable the early diagnosis and management of cancer, organ fibrosis and other diseases, stated the Swansea, England-based company.
Brady, who has agreed to serve as Finance Wales’ representative on the company’s board and consultant to the company, is a professor of information engineering at Oxford University in England and has been involved in the commercialization of imaging technology developed by several enterprises, said Acuitas.